Brought to you by 
Aerovance spins out of Bayer, raises $32mm
19 Mar 2013
Executive Summary
Bayer AG has spun off a new US biopharmaceutical company called Aerovance (therapeutics for inflammatory, autoimmune, and respiratory diseases), which raised $32mm with its first institutional venture financing. Apax Partners led the round and was joined by Lehman Brothers, NGN Capital, and Burrill & Co.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aerovance spins out of Bayer, raises $32mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice